Overview
Could incretin receptor agonists – drugs already transforming the treatment of obesity and diabetes – hold the key to repairing the brain in progressive multiple sclerosis? This question is at the heart of a new collaborative research programme at the University of Cambridge. The post will be based across the laboratories of Professor Clémence Blouet (Institute of Metabolic Science) and Professor Ragnhildur Thóra Káradóttir (Cambridge Stem Cell Institute; Director of the MS Society Cambridge Centre for Myelin Repair), University of Cambridge.
Responsibilities
* Work across both laboratories to test whether long‑acting incretin receptor agonists can promote remyelination, protect neurons, and create a pro‑regenerative environment for brain repair.
* Create focal toxin‑induced demyelinating lesion models in defined circuits.
* Perform stereotaxic surgery and pharmacological interventions.
* Conduct in‑vivo electrophysiological recordings of neuronal activity.
* Perform quantitative histology and imaging analysis.
* Carry out ultrastructural analysis of remyelination.
* Conduct mechanistic profiling including single‑nucleus transcriptomics.
Qualifications
* PhD in neuroscience or a related discipline (or close to completion).
* Strong background in in‑vivo rodent work, including stereotaxic surgery.
* Experience with histology, imaging, or electrophysiological techniques, particularly in‑vivo.
* Highly organised, able to work both independently and collaboratively.
* Strong analytical and communication skills.
Appointment at Research Associate level is dependent on completing a PhD. Candidates who have yet to receive their PhD will be appointed at Research Assistant level (Grade 5) with reclassification to Research Associate (Grade 7) upon award.
The University actively supports equality, diversity and inclusion and encourages applications from all sections of society. The University has a responsibility to ensure that all employees are eligible to live and work in the UK.
J-18808-Ljbffr